Statera BioPharma Net Income

Statera BioPharma (STAB) currently reports a net income of $-100M as of September 2022. That compares with $-15M in the prior-year period — down 614.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Statera BioPharma's net income history and peer comparisons.

Statera BioPharma's net income decreased from $-15M to $-100M — a 614.0% year-over-year decrease (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Statera BioPharma's net income of $-100M is lower than the Healthcare sector average of $16B. That is roughly 100.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Statera BioPharma reported $-100M in net income as of September 2022. That compares with $-15M in the prior-year period — down 614.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Statera BioPharma, and consider following STAB for alerts when major investors trade the stock.